Series
Procedures on upper gastrointestinal tract
Status
Published
Date
Number of report
021
Minimally invasive endoluminal procedures for gastro-esophageal reflux disease (GERD)
Ask the expert
Report presents summary of reimbursement situation for procedures to treat gastro-esophageal reflux disease (GERD) in European countries.
Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations).
Four minimally invasive procedures are considered in the report:
- Radiofrequency ablation
- Endoscopic plication and suturing
- Injection of bulking agents
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- France
- Germany
- Italy
- Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of devices for endoluminal treatment of gastro-esophageal reflux disease (GERD) include:
Radiofrequency ablation
- Mederi Therapeutics (Stretta System)
- Medtronic (Barrx radiofrequency ablation system)
Endoscopic plication and suturing
- Apollo Endosurgery (OverStitch Endoscopic Suturing System)
- C.R.Bard (EndoCinch device)
- Endogastric Solutions (EsophyX System)
- Medigus (SRS Endoscopic Stapling System)
- Medtronic (Gatekeeper Reflux Repair System)
Injection of bulking agents
- Carbon Medical Technologies (Durasphere GR)
Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants
- Boston Scientific (Enteryx Device)
- Medtronic (Gatekeeper Reflux Repair System)
Table of content is not available at the moment.
16
Mar 2023
In January-February 2023, Health Technology Wales published sixteen Medtech-related Topic Exploration Reports (TER), including stereotactic radiosurgery, percutaneous implantation of pulmonary artery pressure sensors, ambulatory patch ECG devices, and others; however, Health Technology Wales will not proceed with full appraisals on these topics. No Guidance was released for Medtech in January-February 2023.
Read more10
Mar 2023
In February 2023, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (transvenous obliteration for gastric varices, biodegradable spacer to reduce rectal toxicity during radiotherapy for prostate cancer), one new Health Technology Evaluation (guided self-help digital cognitive behavioural therapy), and two new Medtech Innovation Briefings (LIVERFASt, and Ambu aScope 4 RhinoLaryngo). Also, one new clinical guideline was published, and one was updated.
Read more08
Mar 2023
On February 23, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, recommending the transfer to standard care for another three completed projects. The projects relate to preventing the family risk of colorectal carcinoma, shared decision-making in the hospitals, and digitally supported drug therapy management.
Read more23
Feb 2023
On February 1, 2023, the Treatment Council made its first two recommendations based on the major analysis reports regarding handheld focused ultrasound in emergency medicine and artificial intelligence as decision support for colonoscopy. The adoption of these technologies was not recommended.
Read more03
Feb 2023
On January 30, 2023, the Institute for the Hospital Remuneration System (InEK) published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2022. The medical technologies belonging to the cardiovascular, eHealth, gastrointestinal, neuromodulation, neurovascular, peripheral vascular, orthopedic, and other technology groups obtained positive status 1.
Read more